The pathogenesis of diabetic retinopathy: Old concepts and new questions

Eye

Volumn 16, Issue 3, 2002, Pages 242-260

  Cai, J ^a   Boulton, M ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Diabetic retinopathy; Growth factor; Hyperglycaemia; Hypoxia; Neovascularization; Pericytes; Retina endothelial cells

Indexed keywords

GROWTH FACTOR; PIGMENT EPITHELIUM DERIVED FACTOR; PLACENTAL GROWTH FACTOR; UNCLASSIFIED DRUG; VASCULOTROPIN;

BASEMENT MEMBRANE; CONTROLLED STUDY; DIABETIC RETINOPATHY; HUMAN; HYPERGLYCEMIA; PATHOGENESIS; PERICYTE; REGULATORY MECHANISM; RETINA BLOOD VESSEL; RETINA CAPILLARY; REVIEW; SIGNAL TRANSDUCTION; STAGING;

EID: 0036269326     PISSN: 0950222X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.eye.6700133     Document Type: Review

References (277)

1. Somatomedin in insulin-dependent diabetes mellitus
2. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus
3. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
4. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: A randomized prospective 6-year study
5. Diabetic retinopathy: Early functional changes
6. Clinical usefulness of measuring urinary polyol excretion by gas-chromatography/mass-spectrometry in type 2 diabetes to assess polyol pathway activity
7. Intracellular protein glycation in cultured retinal capillary pericytes and endothelial cells exposed to high-glucose concentration
8. The role of oxidative stress in diabetic retinopathy
9. The role of protein kinase C in the development of the complications of diabetes
10. Diabetes downregulates GLUTI expression in the retina and its microvessels but not in the cerebral cortex or its microvessels
11. Regulation of glucose transporters during development of the retinal pigment epithelium
12. Enhancement of glucose transport by vascular endothelial growth factor in retinal endothelial cells
13. The blood-reinal barrier in diabetes during puberty
14. Blood-retinal barrier permeability and its relation to progression of retinopathy in patients with type 2 diabetes. A four-year follow-up study
15. Overview of studies on metabolic and vascular regulatory changes in early diabetic retinopathy
16. Central retinal artery innervation. Absence of adrenergic innervation to the intraocular branches
17. Endothelial dysfunction in the pulmonary vascular bed
18. Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man
19. Endothelium-derived nitric oxide in the control of tissue perfusion and oxygen supply: Physiological and pathophysiological implications
20. Nitric oxide regulates basal systemic and pulmonary vascular resistance in healthy humans
21. Comparative pharmacology of endothelium-derived relaxing factor, nitric oxide and prostacyclin in platelets
22. Mediators of leukocyte adhesion in rat mesenteric venules elicited by inhibition of nitric oxide synthesis
23. Nitric oxide: An endogenous modulator of leukocyte adhesion
24. Nitric oxide and prostacyclin. Divergence of inhibitory effects on monocyte chemotaxis and adhesion to endothelium in vitro
25. Nitrovasodilators inhibit thrombin-induced platelet-activating factor synthesis in human endothelial cells
26. Interaction of transmural pressure and shear stress in the transport of albumin across the rabbit aortic wall
27. Vascular smooth muscle cell-directed overexpression of heme oxygenase-1 elevates blood pressure through attenuation of nitric oxide-induced vasodilation in mice
28. Preferential elevation of protein kinase C isoform beta II and diacylglycerol levels in the aorta and heart of diabetic rats: Differential reversibility to glycemic control by islet cell transplantation
29. Insulin's effect on protein kinase C and diacylglycerol induced by diabetes and glucose in vascular tissues
30. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor
31. Oxidative stress and diabetic vascular complications
32. Aldose reductase and the role of the polyol pathway in diabetic nephropathy
33. The linked roles of nitric oxide, aldose reductase and (Na+, K+)-ATPase in the slowing of nerve conduction in the streptozotocin diabetic rat
34. Hyperglycaemia: The bridge between non-enzymatic glycation and oxidative stress in the pathogenesis of diabetic complications
35. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes
36. Lactacystin stimulates arachidonic acid metabolism in rat liver cells: Effects of cell density on arachidonic acid release, PGI2 production and cyclooxygenase activity
37. Prostaglandin E2-induced sensitization of bradykinin-evoked responses in rat dorsal root ganglion neurons is mediated by cAMP-dependent protein kinase A
38. Retinal expression, regulation, and functional bioactivity of prostacyclin-stimulating factor
39. The mechanism of thrombin-induced prostacyclin synthesis in human endothelial cells with reference to the gene transcription of prostacyclin-related enzymes and Ca2+ kinetics
40. Heterogeneous distribution of endothelium-dependent relaxations resistant to NG-nitro-L-arginine in rats
41. Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors
42. Cytochrome P450 2C is an EDHF synthase in coronary arteries
43. Pharmacological evaluation of an epoxide as the putative hyperpolarizing factor mediating the nitric oxide-independent vasodilator effect of bradykinin in the rat heart
44. Bioassay of an endothelium-derived hyperpolarizing factor from bovine coronary arteries: Role of a cytochrome P450 metabolite
45. Characterization of endothelium-derived hyperpolarizing factor as a cytochrome P450-derived arachidonic acid metabolite in mammals
46. Role of PG12 and epoxyeicosatrienoic acids in relaxation of bovine coronary arteries to arachidonic acid
47. Hydrogen peroxide is an endothelium-derived hyperpolarizing factor in mice
48. Extracellular K(+)-induced hyperpolarizations and dilatations of rat coronary and cerebral arteries involve inward rectifier K(+) channels
49. Gap junctional communication underpins EDHF-type relaxations evoked by ACh in the rat hepatic artery
50. Endothelial dysfunction in diabetes
51. Endothelin-1-induced vasoconctriction in humans. Reversal by calcium channel blockade but not by nitrovasodilators or endothelium-derived relaxing factor
52. Endothelin-1 selectively contracts portal vein through both ETA and ETB receptors in isolated rabbit liver
53. Constriction of mouse hepatic venules and sinusoids by endothelins through ETB receptor subtype
54. Endothelin-1 as a mediator of endothelial cell-pericyte interactions in bovine brain capillaries
55. 2+ channel in vascular smooth muscle
56. Activation of phospholipase A2 by endothelin in cultured vascular smooth muscle cells
57. Cellular mechanism of action by a novel vasoconstrictor endothelin in cultured rat vascular smooth muscle cells
58. Role of vasoactive factors in the pathogenesis of early changes in diabetic retinopathy
59. Role of protein kinase C alpha and mitogen-activated activated protein kinases in endothelin-1-stimulation of cytosolic phospholipase A2 in iris sphincter smooth muscle
60. Endothelin-1 activates p38 mitogen-activated protein kinase and cytosolic phospholipase A2 in cat iris sphincter smooth muscle cells
61. Losartan inhibits thromboxane A2-induced platelet aggregation and vascular constriction in spontaneously hypertensive rats
62. The effect of cyclic GMP on rabbit corporal smooth muscle tone and its modulation by cyclo-oxygenase products
63. Superoxide anion is an endothelium-derived contracting factor
64. Topical hyperglycemia rapidly suppresses EDRF-mediated vasodilation of normal rat arterioles
65. Eicosanoid profile in cultured human pulmonary artery smooth muscle cells treated with IL-1 beta and TNF alpha
66. Diabetes-like proliferative retinal changes in galactose-fed dogs
67. Regional cerebral blood flow (rCBF) and cerebral vasoreactivity in patients with retinal ischaemic symptoms
68. Aldose reductase inhibition prevents glucose-induced apoptosis in cultured bovine retinal microvascular pericytes
69. In vitro inhibition of glucose phosphorylation by an aldose-reductase inhibitor (Tolrestat) in some non-insulin-sensitive rabbit tissues
70. The development of electroretinogram abnormalities and the possible role of polyol pathway activity in diabetic hyperglycemia and galactosemia
71. Degenerated intramural pericytes ('ghost cells') in the retinal capillaries of diabetic rats
72. Effects of polyol-pathway inhibition and dietary myo-inositol on glomerular hemodynamic function in experimental diabetes mellitus in rats
73. Aldose reductase and its inhibition in the control of diabetic complications
74. Aldose reductase gene expression and osmotic dysregulation in cultured human retinal pigment epithelial cells
75. Synthesis of flavenoids and their effects on aldose reductase and sorbitol accumulation in streptozotocin-induced diabetic rat tissues
76. Polyol formation and NADPH-dependent reductases in dog retinal capillary pericytes and endothelial cells
77. Polyol pathway activation and glutathione redox status in non-insulin-dependent diabetic patients
78. Alpha-lipoic acid: Effect on glucose uptake, sorbitol pathway, and energy metabolism in experimental diabetic neuropathy
79. Age-dependent accumulation of N epsilon-(carboxymethyl)lysine and N epsilon-(carboxymethyl)hydroxylysine in human skin collagen
80. Amadorins: Novel post-Amadori inhibitors of advanced glycation reactions
81. Advanced glycation: AAn important pathological event in diabetic and age related ocular disease
82. The role of oxidative stress in diabetic retinopathy
83. Effects of inhibition of glycation and oxidative stress on the development of cataract and retinal vessel abnormalities in diabetic rats
84. Abnormalities of retinal metabolism in diabetes or galactosemia: ATPases and glutathione
85. Superoxide dismutase inhibits lipid peroxidation in micelles
86. Catalase/superoxide dismutase (sod) and catalase/paraoxonase (pon) ratios may implicate poor glycemic control
87. Antioxidant enzymes and human diseases
88. The glutathione levels are reduced in Goto-Kakizaki rat retina, but are not influenced by aminoguanidine treatment
89. Abnormalities of retinal metabolism in diabetes or experimental galactosemia. IV. Antioxidant defense system
90. F(2) isoprostanes, potential specific markers of oxidative damage in human retina
91. Topical hyperglycemia rapidly suppresses EDRG-mediated vasodilation of normal rat arterioles
92. Endothelium-dependent vasoactive modulation in the ophthalmic circulation
93. Acute hypoxia and hypoxic exercise induce DNA strand breaks and oxidative DNA damage in humans
94. Oxidative DNA damage in diabetes mellitus: Its association with diabetic complications
95. Altered mRNA levels of antioxidant enzymes in pre-apoptotic pericytes from human diabetic retinas
96. Bax is increased in the retina of diabetic subjects and is associated with pericyte apoptosis in vivo and in vitro
97. Retinal capillary pericyte apoptosis in early human diabetic retinopathy
98. Capillary lesions develop in retina rather than cerebral cortex in diabetes and experimental galactosemia
99. Vascular lesions in diabetes are distributed non-uniformly within the retina
100. Histological and ultrastructural investigation of retinal microaneurysm development in diabetic patients
101. Changes in diabetic retinal matrix protein mRNA levels in common transgenic mouse strain
102. Glycoprotein deposition in vascular walls of diabetic retinopathy. A histopathological and immunohistochemical study
103. Diabetic preretinal membranes. An immunohisochemical study
104. Fibronectin, laminin, vitronectin and their receptors at newly-formed capillaries in proliferative diabetic retinopathy
105. Early biosynthetic changes in the diabetic-like retinopathy of galactose-fed rats
106. Epiretinal membrane of proliferative diabetic retinopathy: An immunohistochemical study
107. Phenotypic expression of collagen types in mesangial matrix of diabetic and nondiabetic rats
108. Basement membrane and growth factor gene expression in normal and diabetic human retinas
109. Matrix metalloproteinase-2 is associated with tenascin-c in calcific aortic stenosis
110. Increased prevalence of microthromboses in retinal capillaries of diabetic individuals
111. d-Alpha-tocopherol prevents the hyperglycemia induced activation of diacylglycerol (DAG)-protein kinase C (PKC) pathway in vascular smooth muscle cells by an increase of DAG kinase activity
112. Activation of human neutrophils by cytokine-activated endothelial cells
113. Effect of WEB 2086-BS, an antagonist of platelet-activating factor receptors, on retinal vascularity in diabetic rats
114. Production of platelet-activating factor by chick retina
115. Presence of specific platelet-activating factor binding sites in the rat retina
116. Significance of platelet-derived microparticles and activated platelets in diabetic nephropathy
117. Cytometric analysis of high shear-induced platelet microparticles and effect of cytokines on microparticle generation
118. Enhanced shear-induced von Willebrand factor binding to platelets in acute myocardial infarction
119. Effect of erythrocytes and prostacyclin production in the effect of fructose and sorbitol on platelet activation in human whole blood in vitro
120. Decreased degradation of collagen and fibronectin following exposure of proximal cells to glucose
121. Effect of camonagrel, a selective thromboxane synthase inhibitor, on retinal vascularization in experimental diabetes
122. Tyrosine phosphorylation and cytoskeletal reorganization in platelets are triggered by interaction of integrin receptors with their immobilized ligands
123. Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition
124. Phorbol ester stimulates PAF synthesis via the activation of protein kinase C in rat leukocytes
125. The regulation of platelet-activating factor production in endothelial cells. The role of calcium and protein kinase C
126. Exogenous nitric oxide increases neutrophil adhesion to cultured human endothelial monolayers through a protein kinase G dependent mechanism
127. Inhibition of platelet-activating factor synthesis in human neutrophils and platelets by propionyl-L-carnitine
128. Inhibition of activation of human peripheral blood eosinophils by Y-24180, an antagonist to platelet-activating factor receptor
129. Leukocyte-induced vascular protein leakage in cat mesentery
130. Thrombin stimulates the adherence of neutrophils to human endothelial cell in vitro
131. The microcirculation and inflammation: Modulation of leukocyte-enothelial cell adhesion
132. Leukocyte-mediated endothelial cell injury and death in the diabetic retina
133. Modulation of endothelial cell expression of intercellular adhesion molecule 1 by protein kinase C activation
134. Intercellular adhesion molecule-1 gene expression in human endothelial cells. Differential regulation by tumor necrosis factor-alpha and phorbol myristate acetate
135. Mediators of leukocyte adhesion in rat mesenteric venules elicited by inhibition of nitric oxide synthesis
136. Nitric oxide: An endogenous modulator of leukocyte adhesion
137. Mechanics of stimulated neutrophils: Cell stiffening induces retention in capillaries
138. Quantifying leukocyte dynamics and plugging in retinal microcirculation of streptozotosin-induced diabetic rats
139. Increased expression of neutrophil and monocyte adhesion molecules LFA-1 and Mac-1 and their ligand ICAM-1 and VLA-4 throughout the acute phase of implications for leukocyte aggregation and microvascular plugging
140. Activated monocytes and granulocytes, capillary nonperfusion, and neovascularization in diabetic retinopathy
141. Cystoid macular degeneration in experimental branch retinal vein occlusion
142. Retinal vessel abnormalities of phototoxic retinopathy in rats
143. Advanced glycation end products increase retinal vascular endothelial growth factor expression
144. Alternative therapeutic principles in the prevention of microvascular and neuropathic complications
145. Endothelial cell responses to hypoxia: Initiation of a cascade of cellular interactions
146. Role of adhesion molecules in vascular regulation and damage
147. Basic fibroblast growth factor levels in the vitreous of patients with proliferative diabetic retinopathy
148. The mode of development of the vascular system of the retina with observations on its significance for certain retinal diseases
149. Retinal vascularization in health and disease
150. Foveal haemorrhages in diabetic retinopathy. Clinical characteristics and visual outcome
151. Histopathology of diabetic retinopathy in man
152. Laser treatment in diabetes related eye complications
153. Echographic evaluation of a patient with diabetes and dense vitreous hemorrhage: An avulsed retinal vessel may mimic a tractional retinal detachment
154. Oxygen sensing and signaling: Impact on the regulation of physiologically important genes
155. Yeast flavohemoglobin is an ancient protein related to globins and a reductase family
156. Hypoxia regulation of gene transcription
157. Hypoxia-inducible factor 1 alpha and 1 beta proteins share common signaling pathways in human prostate cancer cells
158. Induction of vascular endothelial growth factor by hypoxia is modulated by a phosphatidylinositol 3-kinase/Akt signaling pathway in Ha-ras-transformed cells through a hypoxia inducible factor-1 transcriptional element
159. Hypoxia inducible factor-1 alpha is increased in ischemic retina: Temporal and spatial correlation with VEGF expression
160. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells
161. Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia
162. Vascular permeability/vascular endothelial growth factors: A potential role in the pathogenesis and treatment of vascular diseases
163. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders
164. Role of vascular endothelial growth factor in the regulation of angiogenesis
165. Suppression of vascular endothelial growth factor-mediated endothelial cell protection by surviving targeting
166. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor
167. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor
168. Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family
169. Identification of a new endothelial cell growth factor receptor tyrosine kinase
170. A receptor tyrosine kinase cDNA isolated from a population of enriched primitive hematopoietic cells and exhibiting close genetic linkage to c-kit
171. Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium
172. High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis
173. A single autophosphorylation site on KDR/Flk-1 is essential for VEGF-A-dependent activation of PLC-gamma and DNA synthesis in vascular endothelial cells
174. The 230 kDa mature form of KDR/Flk-1 (VEGF receptor-2) activates the PLC-gamma pathway and partially induces mitotic signals in NIH3T3 fibroblasts
175. VEGF-induced activation of phosphoinositide 3-kinase is dependent on focal adhesion kinase
176. Vascular endothelial growth factor induces expression of connective tissue growth factor via KDR, Flt1, and phosphatidylinositol 3-kinase-akt-dependent pathways in retinal vascular cells
177. VEGF-dependent signaling in retinal microvascular endothelial cells
178. Diacylglycerol generated in CHO cell plasma membrane by phospholipase C is used for triacylglycerol synthesis
179. The mechanism of phospholipase C-gamma1 regulation
180. VEGF localisation in diabetic retinopathy
181. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy
182. Detection of vascular endothelial growth factor messenger RNA and vascular endothelial growth factor-like activity in proliferative diabetic retinopathy
183. Upregulation of retinal vascular endothelial growth factor mRNAs in spontaneously diabetic rats without ophthalmoscopic retinopathy. A possible participation of advanced glycation end products in the early phase of diabetic retinopathy
184. Expression of the VEGF gene family during retinal vaso-obliteration and hypoxia Biochem
185. Hypoxia promotes oxidative base modifications in the pulmonary artery endothelial cell VEGF gene
186. Immunolocalisation of the VEGF receptors FLT-1, KDR, and FLT-4 in diabetic retinopathy
187. Vascular endothelial growth factor and its receptors in control and diabetic rat eyes
188. Vascular endothelial growth factor is present in glial cells of the retina and optic nerve of human subjects with nonproliferative diabetic retinopathy
189. Ocular vascular endothelial growth factor levels in diabetic rats are elevated before observable retinal proliferative changes
190. Vascular endothelial growth factor and severity of nonproliferative diabetic retinopathy mediate retinal hemodynamics in vivo: A potential factor in the progression of nonproliferative diabetic retinopathy
191. Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate
192. Vascular permeability factor/vascular endothelial cell growth factor-mediated permeability occurs through disorganization of endothelial junctional proteins
193. Vascular endothelial growth factor induces VE-cadherin tyrosine phosphorylation in endothelial cells
194. Retinal blood flow alterations during progression of diabetic retinopathy
195. Oligodeoxynucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy
196. Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate
197. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins
198. Recovery from retinopathy in a case of diabetes with Simmond's disease
199. Essential role of growth hormone in ischemia-induced retinal neovascularization
200. A two-year follow-up study of serum insulinlike growth factor-I in diabetics with retinopathy
201. Serum IGF-1 concentration in diabetic retinopathy
202. Insulin-like growth factor I acts as an angiogenic agent in rabbit cornea and retina: Comparative studies with basic fibroblast growth factor
203. IGF-I of serum and vitreous fluid in patients with diabetic proliferative retinopathy
204. Stimulatory effects of insulin and insulin-like growth factor I on migration and tube formation by vascular endothelial cells
205. Receptors and growth promoting effects of insulin and insulin-like growth factors on cells from bovine retinal capillaries and aorta
206. Vascular endothelial growth factor, platelet-derived growth factor, and insulin-like growth factor-1 promote rat aortic angiogenesis in vitro
207. Insulin-like growth factor I acts as an angiogenic agent in rabbit cornea and retina: Comparative studies with basic fibroblast growth factor
208. Src family tyrosine kinases participate in insulin-like growth factor in mitogenic signaling in 3t3-11 cells
209. LY 294002, an inhibitor of phosphatidylinositol 3-kinase, inhibits GH-mediated expression of the IGF-I gene in rat hepatocytes
210. Differences in survival-promoting effects and intracellular signaling properties of BDNF and IGF-1 in cultured cerebral cortical neurons
211. Insulin-like growth factor-I is necessary for neural stem cell proliferation and demonstrates distinct actions of epidermal growth factor and fibroblast growth factor-2
212. Localization of mRNAs for insulin-like growth factor-I (IGF-I), IGF-I receptor, and IGF binding proteins in rat eye
213. Endogenous insulin-like growth factor (IGF) binding proteins cause IGF-1 resistance in cultured fibroblasts from a patient with short stature
214. Vitreous levels of the insulin-like growth factors I and II, and the insulin-like growth factor binding proteins 2 and 3, increase in neovascular eye disease. Studies in nondiabetic and diabetic subjects
215. Intravitreal growth factors in proliferative diabetic retinopathy: Correlation with neovascular activity and glycaemic management
216. Vitreous levels of IGF-I, IGF binding protein 1, and IGF binding protein 3 in proliferative diabetic retinopathy: A case-control study
217. Insulin-like growth factor: Receptor and binding proteins in human retinal endothelial cell cultures of diabetic and non-diabetic origin
218. Modulation of insulin-like growth factor (IGF) and IGF binding protein biosynthesis by hypoxia in cultured vascular endothelial cells
219. Hypoxia stimulates insulin-like growth factor binding protein 1 (IGFBP-1) gene expression in HepG2 cells: A possible model for IGFBP-1 expression in fetal hypoxia
220. Production of IGF-I and IGF binding proteins by retinal cells in vitro
221. Basic fibroblast growth factor is released from endothelial extracellular matrix in a biologically active form
222. Cultured bovine bone cells synthesize basic fibroblast growth factor and store it in their extracellular matrix
223. Basic fibroblast growth factor binds to subendothelial extracellular matrix and is released by heparitinase and heparin-like molecules
224. Basic fibroblast growth factor upregulates the expression of vascular endothelial growth factor in vascular smooth muscle cells. Synergistic interaction with hypoxia
225. Basic fibroblast growth factor is neither necessary nor sufficient for the development of retinal neovascularization
226. Fibroblast growth factor-2 (FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of forming capillaries: An autocrine mechanism contributing to angiogenesis
227. Signal transduction by the platelet-derived growth factor receptor
228. Platelet-derived growth factor receptor signals
229. Oxygen tension regulates the expression of the platelet-derived growth factor-B chain gene in human endothelial cells
230. Hypoxia-mediated induction of acidic/basic fibroblast growth factor and platelet-derived growth factor in mononuclear phagocytes stimulates growth of hypoxic endothelial cells
231. Increased levels of platelet-derived growth factor in vitreous fluid of patients with proliferative diabetic retinopathy
232. Migratory and proliferative effect of platelet-derived growth factor in rabbit retinal endothelial cells: Evidence of an autocrine pathway of platelet-derived growth factor
233. Rat brain capillary endothelial cells express functional PDGF B-type receptors
234. PDGF-BB modulates endothelial proliferation and angiogenesis in vitro via PDGF beta-receptors
235. Platelet-derived growth factor (PDGF) in oncogenesis: Development of a vascular connective tissue stroma in xenotransplanted human melanoma producing PDGF-BB
236. Scatter factor/hepatocyte growth factor gene transfer enhances glioma growth and angiogenesis in vivo
237. Roles of growth factors and of tumor necrosis factor-alpha on liver cell proliferation induced in rats by lead nitrate
238. Expression of hepatocyte growth factor and its receptor c-met in human leukemia-lymphoma cells lines
239. Retinal pigment epithelial cells secrete and respond to hepatocyte growth factor
240. Mechanisms of hepatocyte growth factor-induced retinal endothelial cell migration and growth
241. Scatter factor induces blood vessel formation in vivo
242. Scatter factor promotes motility of human glioma and neuromicrovascular endothelial cells
243. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product
244. Inhibitory effect of hepatocyte growth factor against FaO hepatocellular carcinoma cells may be associated with changes of intracellular signalling pathways mediated by protein kinase C
245. The tyrosine-phosphorylated hepatocyte growth factor/scatter factor receptor associates with phosphatidylinositol 3-kinase
246. HGF-mediated chemotaxis and tubulogenesis require activation of the phosphatidylinositol 3-kinase
247. Potential role of an endothelium-specific growth factor, hepatocyte growth factor, on endothelial damage in diabetes
248. Potentiated angiogenic effect of scatter factor/hepatocyte growth factor via induction of vascular endothelial growth factor: The case for paracrine amplification of angiogenesis
249. Hepatocyte growth factor increases expression of vascular endothelial growth factor and plasminogen activator inhibitor-1 in human keratinocytes and the vascular endothelial growth factor receptor flk-1 in human endothelial cells
250. Hepatocyte growth factor/scatter factor (HGF/SF) induces vascular permeability factor (VPF/VEGF) expression by cultured keratinocytes
251. Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor
252. VEGF receptor subtypes KDR and FLT1 show different sensitivities to heparin and placenta growth factor
253. Placenta growth factor stimulates MAP kinase and mitogenicity but not phospholipase C-gamma and migration of endothelial cells expressing Flt 1
254. A unique signal transduction from FLT tyrosine kinase, a receptor for vascular endothelial growth factor VEGF
255. Placenta growth factor-1 is chemotactic, mitogenic, and angiogenic
256. Heterodimers of placenta growth factor/vascular endothelial growth factor. Endothelial activity, tumor cell expression, and high affinity binding to Flk-1/KDR
257. Expression of placenta growth factor (PIGF) in ischaemic retinal diseases
258. Increased expression of placenta growth factor in proliferative diabetic retinopathy
259. Basement membrane and growth factor gene expression in normal and diabetic human retinas
260. Expression of the VEGF gene family during retinal vaso-obliteration and hypoxia
261. Placenta growth factor and vascular endothelial growth factor B and C expression in microvascular endothelial cells and pericytes. Implication in autocrine and paracrine regulation of angiogenesis
262. Growth factor signaling pathways in vascular development
263. Isolation of angiopoietin-1, a ligand for the Tie2 receptor, by secretion-trap expression cloning
264. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis
265. Requisite role of angiopoietin-1, a ligand for the Tie2 receptor, during embryonic angiogenesis
266. Angiopoietin-1 and its receptor Tie-2 participate in the regulation of capillary-like tubule formation and survival of endothelial cells
267. Angiopoietin-1 induces sprouting angiogenesis in vitro
268. Analysis of Tie receptor tyrosine kinase in haemopoietic progenitor and leukaemia cells
269. Cell type-specific expression of angiopoietin-1 and angiopoietin-2 suggests a role in glioblastoma angiogenesis
270. Angiopoietin 2 expression in the retina: Upregulation during physiologic and pathologic neovascularization
271. Hypoxia and vascular endothelial growth factor selectively up-regulate angiopoietin-2 in bovine microvascular endothelial cells
272. PEDF-a pigment epithelium-derived factor with potent neuronal differentiative activity
273. PEDF: Raising both hopes and questions in controlling angiogenesis
274. Pigment epithelium-derived factor: A potent inhibitor of angiogenesis
275. Loss of the anti-angiogenic pigment epithelium-derived factor in patients with angiogenic eye disease
276. Prevention of ischemia-induced retinopathy by the natural ocular antiangiogenic agent pigment epithelium-derived factor
277. Pigment epithelium-derived factor inhibits retinal and choroidal neovascularization